Physician profile
Soledad Lee
NPI 1063609097
$5,937.65
in general payments reported to CMS, 2019-2025
26 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $113 · 2021: $593 · 2022: $1,209 · 2023: $1,069 · 2024: $1,052 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,363.11 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $836.64 | 2019-2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $467.93 | 2021-2025 | Jynarque |
| Amgen INC. | $428.70 | 2024-2025 | Repatha, Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $385.81 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $273.22 | 2019-2024 | Farxiga |
| Gilead Sciences, INC. | $249.97 | 2022-2024 | Epclusa |
| Phathom Pharmaceuticals, INC. | $246.55 | 2024 | Voquezna |
| Lilly USA, LLC | $226.96 | 2024-2025 | Mounjaro |
| Amarin Pharma, INC. | $144.19 | 2019 | |
| Scilex Pharmaceuticals INC. | $141.13 | 2024 | |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Biohaven Pharmaceuticals, INC. | $124.98 | 2021 | |
| Neurocrine Biosciences, INC. | $122.09 | 2023 | Ingrezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $121.87 | 2022 | |
| Dexcom, INC. | $120.54 | 2023 | Dexcom G7 Gss (161) |
| Corcept Therapeutics | $115.00 | 2024 | Korlym |
| Impel Pharmaceuticals INC. | $114.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.91 | 2019 | |
| Acadia Pharmaceuticals INC | $47.41 | 2024-2025 | Daybue |
| Sunovion Pharmaceuticals INC. | $44.75 | 2020-2021 | |
| Glaxosmithkline, LLC. | $24.00 | 2019 | |
| Vanda Pharmaceuticals INC. | $13.90 | 2023 | Fanapt, Hetlioz |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soledad Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.